LRMR
Larimar Therapeutics, Inc. Common Stock
stockNASDAQ
larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company's lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich's ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.67 | 2026-10-29 | -12.17% | 5.187 |
| 1M | 2.86 | 2026-10-05 | -18.01% | 3.666 |
| 3M | 4.10 | 2026-08-05 | -42.80% | 1.265 |
| 6M | 4.01 | 2026-05-05 | -41.52% | 1.253 |
| 1Y | 3.22 | 2025-11-05 | -27.17% | 1.717 |
| 2Y | 7.36 | 2024-11-05 | -68.14% | — |
| 5Y | 13.14 | 2021-11-05 | -82.15% | 1.160 |
Larimar Therapeutics, Inc. Common Stock (NASDAQ:LRMR) stock price today is $2.35, and today's volume is 1,291,049. LRMR is down 15.036% today. The 30 day average volume is 1.59M. LRMR market cap is $243.61M with 103.88M shares outstanding.